BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

AiCuris 

Friedrich-Ebert-Str. 475
Building 302
Wuppertal    D-42117  Germany
Phone: 49-0-202-31763-0 Fax: 49-0-202-31763-1177


SEARCH JOBS


Industry
Pharmaceutical






 Company News
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir 1/29/2013 10:55:50 AM    More...
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/30/2012 1:02:13 PM    More...
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in Preparation for Phase III 8/7/2012 10:39:46 AM    More...
Results of AiCuris's Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants Meeting Both Primary Efficacy Endpoints to be Presented at International Conferences 4/2/2012 9:50:12 AM    More...
AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis in Human Blood Precursor Cell Recipients 2/14/2012 9:50:00 AM    More...
AiCuris Receives Orphan Drug Designation for Letermovir (AIC246) from FDA 1/5/2012 9:32:17 AM    More...
AiCuris: No Resistant Herpes Simplex Virus (HSV) Observed in Phase II Trial with Herpes Drug AIC316 9/6/2011 11:15:58 AM    More...
AiCuris' HCMV Drug Letermovir (AIC246) Receives Fast Track from FDA, New Data to be Presented at 51st ICAAC 8/29/2011 9:08:41 AM    More...
AiCuris' Novel HSV Compound AIC316 Shows Efficacy in Phase II 7/18/2011 9:34:36 AM    More...
AiCuris Receives Orphan Drug Designation for its Innovative Phase II Drug AIC246 for the Prevention of HCMV Disease 4/21/2011 10:15:55 AM    More...
12

//-->